SCHEMBL9474148

SCHEMBL9474148

Nc1nc2c(-c3ccccc3)cc(OC(F)(F)F)cc2s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
CYP1A2 P05177 3/20 0.55
TP53 P04637 2/20 0.55
LMNA P02545 2/20 0.55
SCN9A Q15858 2/20 0.55
SCN4A P35499 2/20 0.55
GMNN O75496 1/20 0.55
USP2 O75604 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
GAA P10253 1/20 0.55
CYP2C9 P11712 1/20 0.55
PKM P14618 1/20 0.55
ALOX15 P16050 1/20 0.55
NFKB1 P19838 1/20 0.55
SLC6A2 P23975 1/20 0.55
BLM P54132 1/20 0.55
PMP22 Q01453 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9474741 0.80 CYP3A4 (0.59) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL9474613 0.80 RAB9A (0.50) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL4436885 0.78 NPC1 (0.48) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL9475114 0.77 HSD17B10 (0.57) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL9185915 0.77 CYP3A4 (0.56) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL4918805 0.76 PIK3CA (0.50) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
Bromide SCHEMBL9189616 0.76 CYP3A4 (0.55) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL9475348 0.75 CYP3A4 (0.54) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL9188493 0.75 CYP3A4 (0.54) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL9476104 0.74 CYP3A4 (0.52) CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5236940-A Administering for treatment of medical conditions associated with the effects of glutamate; glutamate-induced convulsions; schizophrenia; sleep disorders RHONE-POULENC SANTE (FR) 1993-08-17 US disclosed